To date, three CDK4/6 inhibitors, palbociclib, abemaciclib, and ribociclib are approved for patients with Estrogen Receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER)-negative advanced breast cancer in association with endocrine therapy [51]. Here, ESR1 is linked to breast cancer.